Philadelphia’s startup ecosystem climbs 15 spots into the top 30 worldwide, report says
Philadelphia’s startup scene is ranked amongst the best-performing in the world according to Startup Genome.
Article from Philadelphia Business Journal
Incyte Announces U.S. FDA Approval of Opzelura™ (ruxolitinib) Cream, a Topical JAK Inhibitor, for the Treatment of Atopic Dermatitis (AD)
The U.S. Food and Drug Administration has approved Opzelura™ cream for short-term and non-continuous chronic treatment of atopic dermatitis.
Article from Business Wire
Penn Medicine Awarded $6 Million to Advance Understanding of Human Genome Function in Health and Disease
Penn Medicine is one of 30 sites chosen by the National Institute of Health to serve as an Impact of Genomic Variation on Function investigator.
Article from Penn Medicine
FDA clears first-of-its-kind trial to see if CRISPR gene editing can cure HIV
The FDA has cleared a company attempting to use CRISPR gene-editing to cure HIV to begin clinical trials.
Article from Endpoints News
Rite Aid Corp. to move HQ to Philadelphia Navy Yard
Rite Aid Corp. signed a lease for a 23,500 square foot space at 1200 Intrepid Ave for their “enterprise headquarters” as part of an effort to redefine how they envision their employees working as a result of the pandemic.
Article from Philadelphia Business Journal
Drexel soars 30 spots to tie Temple in latest U.S. News college rankings
Temple, Drexel, and other Pennsylvania schools are named as the top colleges in the nation according to the U.S. News & World Report.
Article from Philadelphia Business Journal
Cancer giant Roche splashes into cell therapy with $3B+ Adaptimmune deal for off-the-shelf drugs
Roche’s Genetech has signed a deal to partner with Adaptimmune on off-the-shelf T cell therapies.
Article from Endpoints News
Penn spinout led by veteran pharma execs emerges from stealth mode, raises $50M to advance gene-editing technology
Director of the University of Pennsylvania’s gene therapy program, Dr. James Wilson, has formed a company specializing in gene editing.
Article from Philadelphia Business Journal
Engineering CAR T Cells to Deliver Endogenous RNA Wakes Solid Tumors to Respond to Therapy
A new study from Penn Medicine demonstrates a naturally occurring RNA can activate the body’s own natural T cells to seek out cancer cells that may have escaped recognition by CAR T cells.
Article from Penn Medicine